flysyn
mAbexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 7, 2017 (NCT02789254)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
Tyrosine-protein kinase receptor FLT3 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650288 ↗
Also known as
- flysyn
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02789254 | Phase 1/Phase 2 (Phase 2) | Feb 7, 2017 | Synimmune GmbH, University of Tuebingen |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Synimmune GmbH | For profit | 1 | 0 | 1 | 2017 |
| University of Tuebingen | Academic/Hospital | 1 | 1 | 1 | 2017 |
2 organizations
Page 1 / 1